Clinical Characteristics and Prognosis of Acute Myeloid Leukemia Patients with Protein Tyrosine Phosphatase Non-Receptor Type 11 Gene Mutation

References

• Prada-Arismendy J, Arroyave JC, Rothlisberger S. Molecular biomarkers in acute myeloid leukemia. Blood Rev. 2017;31(1):63–76. doi:10.1016/j.blre.2016.08.005
   PubMed Web of Science ®Google Scholar
• De Kouchkovsky I, Abdul-Hay M. ‘Acute myeloid leukemia: a comprehensive review and 2016 update’. Blood Cancer J. 2016;6(7):e441–e441. doi:10.1038/bcj.2016.50
   PubMed Web of Science ®Google Scholar
• Chan RJ, Feng GS. PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase. Blood. 2007;109(3):862–867. doi:10.1182/blood-2006-07-028829
   PubMed Web of Science ®Google Scholar
• Quintana E, Schulze CJ, Myers DR, et al. Allosteric Inhibition of SHP2 Stimulates Antitumor Immunity by Transforming the Immunosuppressive Environment. Cancer Res. 2020;80(13):2889–2902. doi:10.1158/0008-5472.CAN-19-3038
   PubMed Web of Science ®Google Scholar
• Xu D, Qu CK. Protein tyrosine phosphatases in the JAK/STAT pathway. Front Biosci. 2008;13(13):4925–4932. doi:10.2741/3051
   PubMedGoogle Scholar
• Wu CJ, O’Rourke DM, Feng GS, Johnson GR, Wang Q, Greene MI. The tyrosine phosphatase SHP-2 is required for mediating phosphatidylinositol 3-kinase/Akt activation by growth factors. Oncogene. 2001;20(42):6018–6025. doi:10.1038/sj.onc.1204699
   PubMed Web of Science ®Google Scholar
• Valero V 3rd, Pawlik TM, Anders RA. Emerging role of Hpo signaling and YAP in hepatocellular carcinoma. J Hepatocellular Carcinoma. 2015;2:69–78. doi:10.2147/JHC.S48505
   PubMedGoogle Scholar
• Zhang J, Zhang F, Niu R. Functions of Shp2 in cancer. J Cell Mol Med. 2015;19(9):2075–2083. doi:10.1111/jcmm.12618
   PubMed Web of Science ®Google Scholar
• Zhang ZY. Protein tyrosine phosphatases: structure and function, substrate specificity, and inhibitor development. Annu Rev Pharmacol Toxicol. 2002;42:209–234. doi:10.1146/annurev.pharmtox.42.083001.144616
   PubMed Web of Science ®Google Scholar
• Yuan X, Bu H, Zhou J, Yang CY, Zhang H. Recent Advances of SHP2 Inhibitors in Cancer Therapy: current Development and Clinical Application. J Med Chem. 2020;63(20):11368–11396. doi:10.1021/acs.jmedchem.0c00249
   PubMed Web of Science ®Google Scholar
• Jongmans MC, Van der Burgt I, Hoogerbrugge PM, et al. Cancer risk in patients with Noonan syndrome carrying a PTPN11 mutation. Eur J Hum Genet. 2011;19(8):870–874. doi:10.1038/ejhg.2011.37
   PubMed Web of Science ®Google Scholar
• Song Y, Zhao M, Zhang H, Yu B. Double-edged roles of protein tyrosine phosphatase SHP2 in cancer and its inhibitors in clinical trials. Pharmacol Ther. 2022;230:107966. doi:10.1016/j.pharmthera.2021.107966
   PubMed Web of Science ®Google Scholar
• Nabinger SC, Chan RJ. Shp2 function in hematopoietic stem cell biology and leukemogenesis. Curr Opin Hematol. 2012;19(4):273–279. doi:10.1097/MOH.0b013e328353c6bf
   PubMed Web of Science ®Google Scholar
• Chan G, Cheung LS, Yang W, et al. Essential role for Ptpn11 in survival of hematopoietic stem and progenitor cells. Blood. 2011;117(16):4253–4261. doi:10.1182/blood-2010-11-319517
   PubMed Web of Science ®Google Scholar
• Alhumaid MS, Dasouki MJ, Ahmed SO, et al. Comprehensive Genomic Analysis of Noonan Syndrome and Acute Myeloid Leukemia in Adults: a Review and Future Directions. Acta Haematol. 2020;143(6):583–593. doi:10.1159/000505715
   PubMed Web of Science ®Google Scholar
• Murakami N, Okuno Y, Yoshida K, et al. Integrated molecular profiling of juvenile myelomonocytic leukemia. Blood. 2018;131(14):1576–1586. doi:10.1182/blood-2017-07-798157
   PubMed Web of Science ®Google Scholar
• Stasik S, Eckardt JN, Kramer M, et al. Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia. Blood Adv. 2021;5(17):3279–3289. doi:10.1182/bloodadvances.2021004631
   PubMed Web of Science ®Google Scholar
• Alfayez M, Issa GC, Patel KP, et al. The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia. Leukemia. 2021;35(3):691–700. doi:10.1038/s41375-020-0920-z
   PubMed Web of Science ®Google Scholar
• Swoboda DM, Ali NA, Chan O, et al. PTPN11 mutations are associated with poor outcomes across myeloid malignancies. Leukemia. 2021;35(1):286–288. doi:10.1038/s41375-020-01083-3
   PubMed Web of Science ®Google Scholar
• Hou HA, Chou WC, Lin LI, et al. Characterization of acute myeloid leukemia with PTPN11 mutation: the mutation is closely associated with NPM1 mutation but inversely related to FLT3/ITD. Leukemia. 2008;22(5):1075–1078. doi:10.1038/sj.leu.2405005
   PubMed Web of Science ®Google Scholar
• Fobare S, Kohlschmidt J, Ozer HG, et al. Molecular, clinical, and prognostic implications of PTPN11 mutations in acute myeloid leukemia. Blood Adv. 2022;6(5):1371–1380. doi:10.1182/bloodadvances.2021006242
   PubMed Web of Science ®Google Scholar
• Kishtagari A, Levine RL, Viny AD. Driver mutations in acute myeloid leukemia. Curr Opin Hematol. 2020;27(2):49–57. doi:10.1097/MOH.0000000000000567
   PubMed Web of Science ®Google Scholar
• Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. N Engl J Med. 2016;374(23):2209–2221. doi:10.1056/NEJMoa1516192
   PubMed Web of Science ®Google Scholar
• Patel JP, Gonen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366(12):1079–1089. doi:10.1056/NEJMoa1112304
   PubMed Web of Science ®Google Scholar
• Mardis ER, Ding L, Dooling DJ, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 2009;361(11):1058–1066. doi:10.1056/NEJMoa0903840
   PubMed Web of Science ®Google Scholar
• Ley TJ, Miller C, et al.; Cancer Genome Atlas Research N. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368(22):2059–2074.
   PubMed Web of Science ®Google Scholar
• McNerney ME, Brown CD, Peterson AL, et al. The spectrum of somatic mutations in high-risk acute myeloid leukaemia with −7/del(7q). Br J Haematol. 2014;166(4):550–556. doi:10.1111/bjh.12964
   PubMed Web of Science ®Google Scholar
• Shen D, Chen W, Zhu J, et al. Therapeutic potential of targeting SHP2 in human developmental disorders and cancers. Eur J Med Chem. 2020;190:112117. doi:10.1016/j.ejmech.2020.112117
   PubMed Web of Science ®Google Scholar
• Tartaglia M, Gelb BD. Germ-line and somatic PTPN11 mutations in human disease. Eur J Med Genet. 2005;48(2):81–96. doi:10.1016/j.ejmg.2005.03.001
   PubMed Web of Science ®Google Scholar
• Tartaglia M, Martinelli S, Stella L, et al. Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease. Am J Hum Genet. 2006;78(2):279–290. doi:10.1086/499925
   PubMed Web of Science ®Google Scholar
• Nucifora G. The EVI1 gene in myeloid leukemia. Leukemia. 1997;11(12):2022–2031. doi:10.1038/sj.leu.2400880
   PubMed Web of Science ®Google Scholar
• Aytekin M, Vinatzer U, Musteanu M, Raynaud S, Wieser R. Regulation of the expression of the oncogene EVI1 through the use of alternative mRNA 5’-ends. Gene. 2005;356:160–168. doi:10.1016/j.gene.2005.04.032
   PubMed Web of Science ®Google Scholar
• Groschel S, Lugthart S, Schlenk RF, et al. High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities. J Clin Oncol. 2010;28(12):2101–2107. doi:10.1200/JCO.2009.26.0646
   PubMed Web of Science ®Google Scholar
• Newell LF, Cook RJ. Advances in acute myeloid leukemia. BMJ. 2021;375:n2026. doi:10.1136/bmj.n2026
   PubMedGoogle Scholar